Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
The WAINZUA pre-filled pen is portable, offering patients the flexibility to self-administer in their preferred environment.
Offer your patients flexibility in administration1,2
*If not used within 6 weeks, it should be discarded. Store in the original package to protect from light. Do not freeze. Do not expose to heat.
The first injection administered by the patient or caregiver should be performed under the guidance of an appropriately qualified healthcare professional.
Patients and/or caregivers should be trained in the subcutaneous administration of WAINZUA.1
The WAINZUA Homecare Service, provided by HealthNet Homecare, is a patient support service developed and funded by AstraZeneca UK that allows patients to arrange the delivery of their medication for when it suits them.
This service is available only to eligible patients at healthcare organisations that have formally signed up to it.
The WAINZUA Homecare Service includes:
Dispensing and home delivery of medication
(including text message delivery reminder service)
Clinical waste collection/disposal
At-home device training for patients and/or caregivers wanting to self-administer; Up to four face-to-face nurse-led visits. The first visit will always be face-to-face. Subsequent visits can be face-to-face or virtual†
Provision of funded associated ancillaries
Nurse administration is available for patients not wanting to self-administer
Provision of patient information and support materials‡
Patient self-administration competency assessment
Optional annual phlebotomy from Month 18 following the first dose of WAINZUA
†Where appropriate and agreed with the Trust. HealthNet Homecare provide video conferencing via their internal telephony system 3CX, which is secure and UK hosted, but isn't DTAC approved as there was no requirement to do so at the time of commissioning the service. However, 3CX is on HealthNet Homecare's Validation Roadmap;
‡In addition to the standard patient information leaflet in the pack.
WAINZUA is recommended as a 45 mg single dose, administered monthly by subcutaneous injection.1
Dosing considerations
Special populations1
No dose adjustments are required in elderly patients (≥65 years of age).
No dose adjustment is necessary in patients with mild to moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥45 to <90 ml/min/1.73 m2).
WAINZUA has not been studied in patients with eGFR <45 ml/min/1.73 m2 or end-stage renal disease and should only be used in these patients if the anticipated clinical benefit outweighs the potential risk.
No dose adjustment is necessary in patients with mild hepatic impairment. WAINZUA has not been studied in patients with moderate or severe hepatic impairment and should only be used in these patients if the anticipated clinical benefit outweighs the potential risk.
The safety and efficacy of WAINZUA in children and adolescents below 18 years of age have not been established.
There are three steps to the administration of WAINZUA: prep, inject and check.
Important information you need to know before using the WAINZUA pre-filled pen
Before using the pre-filled pen, ensure that WAINZUA has been stored appropriately:1,2
Please view the video below to learn how to administer WAINZUA.
ATTR=transthyretin amyloidosis; ATTRv=hereditary transthyretin amyloidosis; eGFR=estimated glomerular filtration rate; IU=international units.
GB-62844 | November 2025
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
